Physician profile
Lorissa R Heath
NPI 1619040417
$685.34
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $582 · 2022: $103.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $405.76 | 2021-2022 | |
| Janssen Biotech, INC. | $120.41 | 2021 | |
| Amgen INC. | $42.74 | 2021 | |
| Ucb, INC. | $29.13 | 2021 | |
| Alexion Pharmaceuticals, INC. | $26.86 | 2021 | |
| Ani Pharmaceuticals, INC. | $24.92 | 2022 | |
| Genentech USA, INC. | $18.52 | 2022 | |
| Mallinckrodt Hospital Products INC. | $17.00 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorissa Heath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.